Publications by authors named "C Chevreau"
Objectives: Primary ovarian leiomyosarcomas are exceptionally rare, constituting less than 1% of ovarian tumors, and they typically have a poor prognosis. The available data on the management of these tumors are sparse, with limited publications mainly comprising small retrospective series that include multiple histologic types. The aim is to evaluate the clinical, surgical, pathologic characteristics and clinical outcome of patient affected by primary ovarian leiomyosarcomas.
View Article and Find Full Text PDFIntroduction: Metastatic seminomatous germ cell tumors (mSGCT) are a rare form of cancer. Few studies focused on early relapse (<12 months) after first-line chemotherapy (ChT). We aimed to retrospectively evaluate the impact of salvage retroperitoneal lymph node dissection (RPLND) and high-dose ChT with hematopoietic stem cell transplantation (HDCT-HSCT) in mSGCT patients in a situation of early relapse.
View Article and Find Full Text PDFArticle Synopsis
- A phase 3 trial was conducted to compare the effectiveness of doxorubicin alone versus the combination of doxorubicin and trabectedin in treating advanced leiomyosarcoma.
- The trial involved 150 patients and showed that those receiving the combination therapy had a longer median overall survival (33 months) compared to those receiving doxorubicin alone (24 months), with lower death rates in the combination group.
- While the combination treatment improved progression-free survival (12 months vs. 6 months), it also led to a higher incidence of adverse events and dose reductions compared to doxorubicin alone.
JCO GETUG-13 established that switching patients with poor-prognosis nonseminomatous germ-cell tumors with an unfavorable marker decline to intensified chemotherapy resulted in improved outcomes. Here, we report the GETUG-13 long-term efficacy and toxicity. Two hundred and sixty-three patients with International Germ Cell Cancer Consensus Group poor prognosis received one cycle of bleomycin, etoposide, and cisplatin (BEP): 51 with a favorable tumor marker decline continued with three cycles of BEP (Fav-BEP) and 203 with an unfavorable decline were randomly treated with three BEP (Unfav-BEP) cycles or a dose-dense regimen (Unfav-dose-dense; two cycles of paclitaxel-BEP-oxaliplatin + two cycles of cisplatin, ifosfamide, and bleomycin).
View Article and Find Full Text PDFArticle Synopsis
- The study examines the Lung Immune Prognostic Index (LIPI) to see if it can predict survival in patients with metastatic renal cell carcinoma (mRCC).
- LIPI categorizes patients into groups based on specific blood markers, and results show that those with a better LIPI score have significantly longer overall and progression-free survival.
- The findings indicate that LIPI can be a useful prognostic tool for mRCC patients regardless of the type of treatment they receive, whether it’s immune checkpoint inhibitors or antiangiogenic therapy.